Gilead escapes enhanced damages in $2.5bn Idenix verdict

Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Merck suffers blow as $2.5bn Gilead fine overturned

19 February 2018 District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.

Americas

Idenix $2.5bn ruling will impede innovation, says Amgen

4 February 2020 Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

More on this story

Americas

Merck suffers blow as $2.5bn Gilead fine overturned

19 February 2018 District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.

Americas

Idenix $2.5bn ruling will impede innovation, says Amgen

4 February 2020 Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

More on this story

Americas

Merck suffers blow as $2.5bn Gilead fine overturned

19 February 2018 District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.

Americas

Idenix $2.5bn ruling will impede innovation, says Amgen

4 February 2020 Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Gilead escapes enhanced damages in $2.5bn Idenix verdict

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features